Guidelines for the treatment of hypercalcemia associated with malignancy

Journal of Oncology Pharmacy Practice

Volumn 3, Issue 1, 1997, Pages 31-37

  Nakashima, Lynne ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Bisphosphonates; Guidelines; Hypercalcemia

Indexed keywords

EID: 7844228076     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529700300105     Document Type: Article

References (27)

1. Ralston SH, Gallacher SJ, Patel U., Campbell J., Boyle IT Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med. 1990;112:499-504.
2. Gucalp R., Theriault R., Gill I.,et al.Treatment of cancer-associated hypercalcemia. Arch Intern Med. 1994;154:1935-1944.
3. Theriault RL Hypercalcemia of malignancy: pathophysiology and implications for treatment. Oncology. 1993;7:47-50.
4. Ritch PS Treatment of cancer-related hypercalcemia. Semin Oncol. 1990;17(Suppl 5):26-33.
5. Bilezikian JP Management of acute hypercalcemia. New Engl J Med. 1992;326:1196-1203.
6. Chisholm MA, Mulloy AL, Taylor AT Acute management of cancer-related hypercalcemia. Ann Pharmacother. 1996;30:507-513.
7. Hall TG, Schaiff RA Update on the medical treatment of hypercalcemia of malignancy. Clin Pharm. 1993;12:117-125.
8. Armstrong DK, Ettinger DS Current approaches to treatment of hypercalcemia of malignancy. Modern Med. 1990;45:226 -231.
9. Mundy GR Evaluation and treatment of hypercalcemia. Hosp Pract. 1994;June:79-86.
10. Ralston SH, Patel U., Fraser WD,et al.Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet. 1989;2:1180-1182.
11. Gucalp R., Ritch P., Wiernik PH,et al.Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992;10:134 -142.
12. Kelihan MJ, Mangino PD Pamidronate. Ann Pharmacother. 1992; 26:1262-1269.
13. Fitton A., McTavish D. Pamidronate. Drugs. 1991;41:289-318.
14. Nussbaum SR, Younger J., Vandepol CJ,et al.Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med.1993;95:297-304.
15. Morton AR, Cantrill JA, Craig AE,et al.Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcemia of malignancy. Br Med J. 1988; 296:811-814.
16. Plosker GL, Goa KL Clodronate. a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994;47:945-982.
17. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease. Drugs. 1991;42:919-944.
18. Singer FR, Ritch PS, Lad TE,et al.Treatment of hypercalcemia of malignancy with intravenous etidronate. Arch Intern Med. 1991; 151:471-476.
19. Flores JF, Rude RK, Chapman RA,et al.Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer. 1994;73:2527-2534.
20. Schaiff RAB, Hall TG, Bar RS Medical treatment of hypercalcemia. Clin Pharm. 1989;8:108-121.
21. Green L., Ringenberg QS Current concepts in the management of hypercalcemia of malignancy. Hosp Formul. 1988; 23:268-287.
22. Coleman RE Comment: hypercalcemia of malignancy. Current medical literature. Breast Cancer. London: Royal Society of Medicine Service Ltd. 1990;2:3-9.
23. Becker KL Corticosteroids: many of their side effects are really their actions. Drug Therapy. 1982;Jan:131-139.
24. Ralston SH, Dryburgh FJ, Cowan RA,et al.Comparison of aminohydroxypropylidene diphosphate, Mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia. Lancet. 1985;2:907-910.
25. Green L., Donehower RC Hepatic toxicity of low doses of Mithramycin in hypercalcemia. Cancer Treat Rep. 1984;68:1379-1381.
26. Benedetti RG, Heilman KJ, Gabow PA Nephrotoxicity following single dose Mithramycin therapy. Am J Nephrol. 1983;3: 277-278.
27. Yamreudeewong W., Henann NE, Fazio A.,et al.Possible severe thrombocytopenia associated with a single dose of plicamycin. Ann Pharmacother. 1992;26:1369-1373.